About: An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19
Creator	Biol, Turk Abamor, Şefik Acar, Tayfun Arasoğlu, Tülin Arayici, Pelit Derman, Serap Turgut-Balik, Dilek Topuzoğullari, Murat Uçar, Burcu Uğurel, Erennur
source	Medline; PMC
abstract	SARS-CoV-2 is a new member of the coronavirus family and caused the pandemic of coronavirus disease 2019 (COVID-19) in 2020. It is crucial to design and produce an effective vaccine for the prevention of rapid transmission and possible deaths wcaused by the disease. Although intensive work and research are being carried out all over the world to develop a vaccine, an effective and approved formulation that can prevent the infection and limit the outbreak has not been announced yet. Among all types of vaccines, epitope-based peptide vaccines outshine with their low-cost production, easy modification in the structure, and safety. In this review, vaccine studies against COVID-19 have been summarized and detailed information about the epitope-based peptide vaccines against COVID-19 has been provided. We have not only compared the peptide vaccine with other types of vaccines but also presented comprehensive literature information about development steps for an effective and protective formulation to give an insight into on-going peptide vaccine studies against SARS-CoV-2.
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.3906/biy-2006-1
bibo:pmid	32595358
has license	cc-by
sha1sum (hex)	7459ecf29d386302317352d1c5ec885634a90aad
schema:url	https://doi.org/10.3906/biy-2006-1
resource representing a document's title	An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19
has PubMed Central identifier	PMC7314509
has PubMed identifier	32595358
schema:publication	Turk J Biol
resource representing a document's body	covid:7459ecf29d386302317352d1c5ec885634a90aad#body_text
is schema:about of	named entity 'design strategy' named entity 'studies' named entity 'peptide vaccine' named entity 'COVID' named entity 'preclinical' named entity 'infection' named entity 'adjuvant' named entity 'SARS-CoV-2' named entity 'subunit vaccines' named entity 'Boc protecting group' named entity 'viruses' named entity 'peptides' named entity 'preclinical' named entity 'epitope' named entity 'phospholipids' named entity 'Spike protein' named entity 'lung' named entity 'pathogenesis' named entity 'IFNγ' named entity 'WHO' named entity 'chemically synthesized' named entity 'binding affinity' named entity 'HPLC' named entity 'Th1' named entity 'COVID-19 outbreak' named entity 'immunogenicity' named entity 'Biopharmaceutical Company' named entity 'antigenic' named entity 'Shang' named entity 'protease inhibitors' named entity 'peptide vaccine' named entity 'T-cell' named entity 'Nucleocapsid' named entity 'protein' named entity 'antigens' named entity 'peptide-based' named entity 'Fmoc' named entity 'clinical trials' named entity 'immune responses' named entity 'Alum' named entity 'rhesus macaques' named entity 'SARS-CoV-2' named entity 'MALDI-TOF-MS' named entity 'pathogens' named entity 'epitopes' named entity 'adjuvant' named entity 'pathology' named entity 'SPPS' named entity 'antigenic' named entity 'COVID-19' named entity 'ovalbumin' named entity 'COVID' named entity 'peptide' named entity 'vaccine' named entity 'NIH' named entity 'Antigen-presenting cells' named entity 'epitope' named entity 'peptide vaccine' named entity 'infection' named entity 'vaccine' named entity 'antigenic' named entity 'Cyclic guanosine monophosphate' named entity 'adjuvants' named entity 'cross-reactive' named entity 'lymphocytes' named entity 'protein' named entity 'Hepatitis' named entity 'oil-in-water emulsion' named entity 'reactogenic' named entity 'epitope mapping' named entity 'Vaccine' named entity 'Krammer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software